Nivolumab in Recurrent and/or Metastatic SCCHN

PHASE2CompletedINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2022

Conditions
Recurrent and/or Metastatic Platinum-refractory SCCHN
Interventions
DRUG

Nivolumab Injection

Nivolumab 3 mg/kg, every 2 weeks

Trial Locations (18)

14176

Centre Francois Baclesse, Caen

21079

Centre Georges Francois Leclerc, Dijon

31052

Institut Claudius Regaud, Toulouse

33075

CHU Bordeaux, Bordeaux

34298

ICM Val d'Aurelle, Montpellier

51056

Institut Jean Godinot, Reims

59020

Centre Oscar Lambret, Lille

63011

Centre Jean Perrin, Clermont-Ferrand

67000

Centre Paul Strauss, Strasbourg

75970

Hopital Tenon, Paris

92210

Institut Curie Saint Cloud, Saint-Cloud

94800

Gustave Roussy, Villejuif

Unknown

Institut de Cancérologie de l'Ouest, Angers

Centre Léon Bérard, Lyon

Institut Curie, Paris

Centre Eugène Marquis, Rennes

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

06189

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

UNICANCER

OTHER